New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 19, 2014
04:55 EDTACHC, ACHC, ACHC, BABY, BABY, BABY, CNC, CNC, CNC, INCY, INCY, INCY, AUXL, AUXL, AUXL, HGR, HGR, HGR, ALKS, ALKS, ALKS, ACHN, ACHN, ACHN, MZOR, MZOR, MZOR, LMNX, LMNX, LMNX, IDIX, IDIX, IDIXUBS to hold a conference
Global Healthcare Conference to be held in New York on May 19-21.
News For IDIX;LMNX;MZOR;ACHN;ALKS;HGR;AUXL;INCY;CNC;BABY;ACHC From The Last 14 Days
Check below for free stories on IDIX;LMNX;MZOR;ACHN;ALKS;HGR;AUXL;INCY;CNC;BABY;ACHC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 22, 2014
13:46 EDTCNCCourt upholds Obamacare subsidies, NY Times says
Subscribe for More Information
10:43 EDTCNCAppeals court bars subsidies in health care law
A three-judge panel of the D.C. Circuit Court of Appeals struck down part of President Obama's healthcare law by siding today with plaintiffs who argued that the law barred the government from giving subsidies to people in states that chose not to set up their own insurance marketplaces. The appeals court stated, "Because we conclude that the ACA unambiguously restricts the section 36B subsidy to insurance purchased on Exchanges 'established by the State,' we reverse the district court and vacate the IRSís regulation." Twenty-seven states decided against setting up marketplaces, and another nine states partially opted out, according to the Washington Post.
06:47 EDTCNCCentene up 2.1% following Q2 earnings release
Subscribe for More Information
06:14 EDTCNCCentene sees FY14 EPS $3.70-$3.90, consensus $3.73
Subscribe for More Information
06:12 EDTCNCCentene reports Q2 EPS ex-items 95c, consensus 72c
Reports Q2 revenue $4.02B, consensus $3.66B. Reports Q2 EPS 79c. Reports Q2 premium and service revenues $3.74B.
July 17, 2014
11:12 EDTIDIXOptions with decreasing implied volatility
Subscribe for More Information
07:05 EDTALKSAlkermes announces initiation of Phase 1 study of ALKS 8700 for treatment of MS
Subscribe for More Information
July 14, 2014
10:27 EDTMZORMigdal Insurance & Financial reports 5.16% passive stake in Mazor Robotics
Subscribe for More Information
10:00 EDTIDIXOptions with decreasing implied volatility: SHPG INFY CWH FDO IDIX FAST
09:28 EDTCNCCentene best positioned Medicaid pure play to post Q2 EPS beat, says Sterne Agee
Subscribe for More Information
July 11, 2014
07:38 EDTALKSHouse Energy & Commerce Committee to hold a hearing
Subscribe for More Information
July 10, 2014
07:11 EDTCNCAetna, WellPoint top large-cap Managed Care picks at Jefferies
Jefferies calls Aetna (AET) and WellPoint (WLP) its favorite large-cap picks in the Managed Care space, with Health Net (HNT) its favored name in the small to mid-cap space. The firm believes the market is already expecting strong Q2 results from the sector, and it downgraded UnitedHealth (UNH) to Hold from Buy on valuation and below-peer earnings growth. Jefferies has Buy ratings on Aetna, Health Net, Molina Healthcare (MOH) and WellPoint.
06:23 EDTCNCHealth insurers moving away from fee for service model, NY Times reports
Subscribe for More Information
July 9, 2014
07:04 EDTALKSAlkermes announces notice of allowance for four pipeline candidates
Subscribe for More Information
July 8, 2014
07:34 EDTINCYIncyte achieves $25M milestone for approval of Jakavi in Japan
Incyte Corporation (INCY) has earned a $25M milestone payment from Novartis (NVS) in connection with the approval of Jakavi in Japan for the treatment of patients with myelofibrosis. Incyte will record this amount as contract revenue in the third quarter. Under the Incyte-Novartis Collaboration and License Agreement, Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications and sells ruxolitinib under the name Jakavi. Ruxolitinib is marketed by Incyte in the United States as Jakafi. Novartis also continues to make progress in obtaining formal pricing and reimbursement approval for a third major European country and expects this to occur in the second half of 2014. Once achieved, Incyte will earn an additional $60M milestone payment.
07:17 EDTINCYLeerink raises immuno-oncology market forecast to $36B
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use